Clinical Trial Update: Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating two dosing schedules of adalimumab in adults with moderate to severe chronic plaque psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Abbott | Conditions: Psoriasis | Phase 2 | Status: COMPLETED